Company intelligence / Profile preview
Metabolys
Lyon, Rhône, Francemetabolys.com ↗
- Ownership
- Private
- Employees
- ~2
- Development stage
- Other
01
Overview
Metabolys was a French biopharmaceutical company focused on the discovery and development of small molecule therapeutics for metabolic diseases, specifically type 2 diabetes, nonalcoholic steatohepatitis (NASH), and liver fibrosis. The company's lead candidate, MTBL0036, is an orally active, liver-targeted small molecule that acts as a mitochondrial uncoupler to reduce inflammation, ballooning, and fibrosis. Metabolys utilized a phenotypic screening approach combined with cellular metabolomics to identify novel metabolic drug candidates. The company was founded in 2008 by Gabriel Baverel and was headquartered in Lyon, France, before undergoing liquidation in 2024.
- Therapeutic areas
- EndocrinologyGastroenterology
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Metabolys.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Metabolys.